DOCSLIB.ORG

Glaxosmithkline Aims to Divest Many OTC Brands

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Glaxosmithkline Aims to Divest Many OTC Brands OTC11-02-11p1&28FIN.qxd 8/2/11 11:52 Page 1 11 February 2011 COMPANY NEWS 3 GlaxoSmithKline aims to Valeant expands in CEE 3 with PharmaSwiss deal J&J loses sales of US$1.1bn 4 Boots faces up to tough market 5 divest many OTC brands Key brands boost Novartis OTC sales 6 GSK consumer races ahead 7 laxoSmithKline intends to divest non- to divest the non-core brands as soon as pos- Taisho holds steady in weak market 8 Gcore OTC brands with combined an- sible – hopefully before the end of the year – Vicks shipments lift OTC at P&G 9 nual sales of £500 million (C593 million). depending on buyer interest. Perrigo plans spring Allegra launch 10 Chief executive officer Andrew Witty said The announcement came as GlaxoSmith- Consumer Care grows at Merck & Co 11 the move would enable the company’s Con- Kline reported a 7% rise – 5% at constant ex- Omega reports strong quarter 12 sumer Healthcare division to focus more effec- change rates – in 2010 sales at the Consumer Winter woes hit Boiron 13 tively on its “priority or global” brands as well Healthcare division to £5.01 billion. Sales in Pfizer wants Consumer 14 as its operations in emerging markets. Consumer Healthcare’s OTC Medicines busi- to prove worth A spokesperson for GlaxoSmithKline told ness grew by 5% – 3% at constant exchange OTC bulletin that the company was currently rates – to £2.46 billion. GENERAL NEWS 15 compiling the lists of priority and non-core OTC brands, and hoped to release more details Recent deals with Meda and Valeant Perrigo faces lawsuit over 15 in the second quarter of the year. Non-core OTC Meda has just acquired five brands from its OTC ibuprofen in the US brands in Europe and North America would be GlaxoSmithKline Consumer Healthcare in the MARKETING NEWS 16 the main focus of the initiative,the spokesper- US in two deals worth a total of SEK415 mil- son added, along with certain brands in Aus- lion (C47.2 million) (OTC bulletin,21 January Sanofi-Aventis gets okay 16 tralia, Japan and New Zealand. 2010, page 4). The Swedish company gained for OTC Allegra in the US Explaining the reasons for the move,Witty the Geritol multivitamin, the Feosol iron sup- Meda launches Linicin in UK 17 pointed out that Consumer Healthcare’s prior- plement and another unnamed iron supplement GSK puts body first in new 18 ity or global brands – including Lucozade, Pana- in December,before acquiring the Contac cold Panadol Advance campaign dol and Sensodyne – combined with the divi- and flu line and the Vivarin caffeine supple- Blackmores campaign tells 19 sion’s operations in emerging markets, such as ment in January. The five brands had combin- Australians today’s the day India and China, represented 90% of its sales. ed annual sales of around SEK180 million, McNeil puts £7m behind 22 “The other 10% is essentially a selection of Meda said, and strong profit margins. new Regaine foam in UK about 100 or so fragmented brands, often OTC Meanwhile, Valeant Pharmaceuticals Inter- brands sold in pharmacy, and often only sold national has just agreed to buy all the Cana- FEATURES 24 in one or two countries,”he said, remarking dian and US rights to non-ophthalmic topical Botanicals pose problems 24 that “frankly they are a drag on the growth of formulations of Zovirax from GlaxoSmithKline for regulators this business”. for US$300 million (C221 million). The formu- Witty added that GlaxoSmithKline intended lations are prescription-only in the US. REGULARS Pharmacy viewpoint 20 – Lemsip and Benylin get noticed Coates considers Pfizer set to grab Events – Our regular listing 23 People – Bayer’s Balkema to retire 27 sale of Healthspan Ferrosan business De Vos departs Omega uernsey-based nutrition company Health- fizer is set to expand its Consumer Health- Omega Pharma said its chief operating officer Gspan could be about to change hands. Pcare business by acquiring Ferrosan’s Con- Georges De Vos had left the company by mutual Derek Coates, owner and chief executive sumer Healthcare operation from the private- consent due to “differences in vision”. De Vos departs Omega just 18 months after officer of Healthspan, has appointed the ac- equity group Altor 2003 Fund for an undis- joining the Belgian firm from Novartis (OTC countancy firm Deloitte to “explore the longer- closed amount. bulletin,16 September 2009, page 23). Omega term options with regard to ownership”. Paul Sturman, president of Pfizer Consumer said De Vos’ responsibilities would be taken on Over the past few years, commented Coates, Healthcare, said the Danish business was an by its executive committee until a “new manage- ment structure” had been decided. “several approaches from various companies “excellent strategic fit” that strengthened the ■ Continued on page 27 ■ Continued on page 21 OTC11-02-11p2-3FIN.qxd 8/2/11 11:55 Page 3 COMPANY NEWS OTC Mergers & Acquisitions Business Strategy Valeant expands in CEE Merck might with PharmaSwiss deal sell Consumer erck KGaA has not ruled out selling its aleant Pharmaceuticals International is set eastern Europe – including the Czech Repub- MConsumer Health Care business if it mak- Vto strengthen its position in central and east- lic, Hungary,Poland and Serbia – along with es “economic sense”, according to chief execu- ern Europe (CEE)by acquiring branded gener- operations in Greece and Israel. tive officer Karl-Ludwig Kley. ics and OTC firm PharmaSwiss for C350 million. Established in 2000, PharmaSwiss operates In an interview published in The Financial The price represents approximately 1.9-times primarily as a marketing and distribution part- Times newspaper,Kley said that efforts to dou- PharmaSwiss’ 2010 sales, which Valeant said ner in central and eastern Europe for numerous ble the size of the Consumer Health Care busi- stood at around C180 million. pharmaceutical firms. The company also in-lic- ness over the past three years had been hindered Over the past five years, PharmaSwiss had enses brands from speciality pharmaceutical by high prices of potential acquisitions. “With posted annual sales growth of around 20%, and biotechnology companies, as well as offer- the current pricing environment, I do not see Valeant noted, adding that the company had a ing a portfolio of wholly-owned products in the that we could spend billions to double the busi- presence in 19 countries throughout central and generics and OTC sectors. ness to critical mass on a global scale,”Kley PharmaSwiss’ OTC brands include the Di- commented. cloFlex diclofenac spray – which is also sold Asked whether he would consider selling OTC bulletin under the DoloFlex and SwissRelief names – the Consumer Health Care business, Kley said the MamaVit vitamin and mineral product for he would “never exclude any option” that made 11 February 2011 Number 356 pregnant and nursing women, and the Omega- “economic sense”. Defend food supplement. A spokesperson for Merck KGaA confirm- Editor & Publisher: Deborah Wilkes Michael Pearson, Valeant’s chief executive ed to OTC bulletin that Kley had said divest- Associate Editors: Aidan Fry officer,said PharmaSwiss’ “attractive partner- ment could not be excluded. Kley had not said Mike Rice ing strategy” and “complementary branded ge- the Consumer Health Care business was up for Business Editor: Matt Stewart nerics and OTC portfolio” solidified its position sale, added the spokesperson. Assistant Editors: Joanne Grew, Jenna Lawrence, in central and eastern Europe. In the same interview, however, Kley did rule David Wallace Over time, it was anticipated that Valeant’s out any sale of Merck KGaA’s liquid crystals Advertising Controller: Debi Minal central European business would be integrated operation. into the PharmaSwiss corporate structure, Val- In March 2010, Kley revealed that Merck’s Marketing Manager: Val Davis eant noted, adding that PharmaSwiss’ senior plan to turn its Consumer Heath Care business Editorial, Subscription and Advertising management team would stay with the firm. into “one of the top-10 global OTC players by enquiries should be addressed to: OTC bulletin, OTC Publications Ltd, 54 Creynolds Lane, Solihull, The deal – which is expected to close by the doubling annual sales to C1.0 billion” by 2012 West Midlands B90 4ER, UK. end of the second quarter of 2011 – is Valeant’s (OTC bulletin,29 May 2009, page 20) had been Tel: +44 1564 777550. Fax: +44 1564 777524. first major buy since it completed its merger dealt a blow during 2009 when it missed out E-mail: [email protected]. with Canada’s Biovail in October of last year on two unnamed acquisition targets (OTC bul- Subscriptions (OTC bulletin,15 October 2010, page 3), and letin,17 March 2010, page 1). Annual subscriptions to OTC bulletin in Europe are £625.00 for single copies and £355.00 for additional copies to the same ad- adds to the firm’s European operations, which Merck KGaA’s Consumer Health Care unit dress, including delivery. Subscriptions to addresses outside Eur- are centred on Poland’s ICN Polfa Rezeszow. reported sales up by 6% in 2009 to C467 mil- ope are subject to an additional charge of £30.00 to cover postage. Subscription enquiries in Korea should be directed to Pharma Valeant last expanded its European opera- lion from its portfolio of brands, which includes Koreana Ltd, 14th Floor,KTB Network Building, 826-14 Yeoksam- tions in 2009, firstly by paying US$28 million the Bion and Seven Seas food supplement ranges dong, Kangnam-gu, Seoul 135-080, Korea (Tel: +82 2 554 9591; Fax: +82 2 563 8289; E-mail: [email protected]). (C20 million) for the Polish gel specialist Emo- and the Nasivin nasal decongestant. Advertising Farm (OTC bulletin,15 May 2009, page 9) and OTC Advertising rates and data are available on request from the ad- then by snapping up the rights to several pre- dress above or at www.otc-bulletin.com.
Load more

Recommended publications
  • 2013--Annual-Report-Accounts.Pdf
    Helping people make measurable progress in their lives through learning ANNUAL REPORT AND ACCOUNTS 2013 OUR TRANSFORMATION To find out more about how we are transforming our business go to page 09 EFFICACY To find out more about our focus on efficacy go to page 14 OUR PERFORMANCE For an in-depth analysis of our performance in 2013 go to page 19 Pearson is the world’s leading learning company, with 40,000 employees in more than 80 countries working to help people of all ages to make measurable progress in their lives through learning. We provide learning materials, technologies, assessments and services to teachers and students in order to help people everywhere aim higher and fulfil their true potential. We put the learner at the centre of everything we do. READ OUR REPORT ONLINE Learn more www.pearson.com/ar2013.html/ar2013.html To stay up to date wwithith PPearsonearson throughout the year,r, visit ouourr blog at blog.pearson.comn.com and follow us on Twitteritter – @pearsonplc 01 Heading one OVERVIEW Overview 02 Financial highlights A summary of who we are and what 04 Chairman’s introduction 1 we do, including performance highlights, 06 Our business models our business strategy and key areas of 09 Chief executive’s strategic overview investment and focus. 14 Pearson’s commitment to efficacy OUR PERFORMANCE OUR Our performance 19 Our performance An in-depth analysis of how we 20 Outlook 2014 2 performed in 2013, the outlook 23 Education: North America, International, Professional for 2014 and the principal risks and 32 Financial Times Group uncertainties affecting our businesses.
    [Show full text]
  • Rb-Annual-Report-2012.Pdf
    Reckitt Benckiser Group plc Reckitt Benckiser Group Healthier Happier Annual Report and Financial Statements 2012 Stronger Reckitt Benckiser Group plc Annual Report and Financial Statements 2012 Contents 1 Chairman’s Statement 2 Chief Executive’s Statement 10 Business Review 2012 18 Board of Directors and Executive Committee 19 Report of the Directors 22 Chairman’s Statement on Corporate Governance 24 Corporate Governance Report 30 Statement of Directors’ Responsibilities 31 Directors’ Remuneration Report 38 Independent Auditors’ Report to the members of Reckitt Benckiser Group plc 39 Group income statement 39 Group statement of comprehensive income 40 Group balance sheet 41 Group statement of changes in equity 42 Group cash flow statement 43 Notes to the financial statements 75 Five-year summary 76 Parent Company – Independent Auditors’ Report to the members of Reckitt Benckiser Group plc 77 Parent Company balance sheet 78 Notes to the Parent Company financial statements 84 Shareholder information Chairman’s Statement largest consumer health care category in The Board conducted its regular reviews the world with the acquisition of Schiff of the Company’s brands, geographic area Nutrition International, Inc. (Schiff) and and functional performance together with its leading US brands in the vitamins, detailed reviews of its human resources. minerals and supplements market. There The Board also completed its annual were also a few disposals of non core assessment of corporate governance assets. Net debt at the end of 2012, after including Board performance, corporate paying for dividends, net acquisitions and responsibility, and reputational and organisation restructuring, stood at business risk. £2,426m (2011: £1,795m). AGM Resolutions Your Board proposes an increase in the final The resolutions, which will be voted dividend of +11%, taking it to 78p per upon at our AGM of 2 May 2013 are share, and bringing the total dividend for fully explained in the Notice of Meeting.
    [Show full text]
  • Corporate Social Responsibility Report 2016 Walgreens Boots Alliance Is the First Global Pharmacy-Led, Health and Wellbeing Enterprise
    Corporate Social Responsibility Report 2016 Walgreens Boots Alliance is the first global pharmacy-led, health and wellbeing enterprise. Our purpose is to help people across the world lead healthier and happier lives. Our 2016 Corporate Social Responsibility Report covers the fiscal year that ended 31 August 2016. In this year’s report: Overview Marketplace Introduction ...................................................1 Our CSR goals .............................................2 28 Our vision, purpose and values ................3 Our approach to CSR .................................4 Contributing to the United Nations Sustainable Development Goals .............6 Transparency ........................................... 30 Our impact ...................................................8 Ethical Sourcing ...................................... 30 ........................... About our Company ................................. 10 External Stakeholders 31 Stakeholder engagement ....................... 12 Workplace Community 32 14 Employee Health and Wellbeing ........ 34 Equal Opportunities .............................. 36 Health and Wellbeing ............................. 16 Health and Safety ...................................37 Young People ........................................... 17 ...................................... Cancer Programs .....................................20 About this report 38 Data management process ................ 38 Environment Data ............................................................ 38 Community data
    [Show full text]
  • OSB Participant List by Research Area
    OSB Participant List by Research Area Contact Centers (CC) • AARP • Air Products and • American Drug Stores Chemicals • AAA • ABB • American Electric Power • Airbus • Accor • Abbott • American Express • Alcatel Lucent • American Electric Power • Abengoa • American International • Alcoa Group • American International • Abu Dhabi National Group Energy Company • Alcon • American Stores Company • Austin Energy • ACC Limited • Alfa • American Water • Bank of America • Access Insurance Holdings • Algonquin Power & • Amgen Utilities • Blue Cross Blue Shield • Accord Holdings • AMIL • ALH Group • Charles Schwab & • ACE • AmInvestment Bank Company • Alitalia • Acea • AMR • Citigroup • ALK Abello • Acer • Amssi • Citizens Gas • Alkermes • Acxiom • Amtran Logistics • Clarke American • Allergan • Adelaide Clinic Holdings • Andrew Corporation • CPS Energy • Alliance & Leicester • Adidas • Anglian Water Services • Direct Energy • Alliance Boots • Advance Food Company • Anritsu • Federal Reserve Bank of • Alliant Techsystems Minneapolis • Advance Publications • Anschutz • Allianz • John Deere • Advanced Coating • Apache • Allied Irish Banks • Technologies Louisville Water Company • Apex Equity Holdings • Advanced Semiconductor • Allstate Insurance • Manila Electric Company Engineering Company • Apple • • • Mellon Financial Adventist Health System Ally Financial • Arcadia Housing • • • MetLife Aegon Alon USA Energy • Arcos Dorados Holdings • • • Morgan Stanley AEON AlpTransit Gotthard • Ardent Health Services • • • NetBank Aera Energy Alstom • Argos •
    [Show full text]
  • Betterbusiness Betterfinancials How We Drive Growth and Outperformance
    Reckitt Benckiser Group plc Annual Report and Financial2015 Statements betterbusiness 2015 Reckitt Benckiser Group plc (RB) Annual Report and Financial Statements We make a difference to people’s lives through a trusted portfolio of brands, across consumer health, hygiene and home. Our vision Our purpose A world where people are To make a difference, by healthier and live better. giving people innovative solutions for healthier lives and happier homes. Our strategy betterbusiness betterfinancials How we drive growth and outperformance Chief Executive’s Review on pages 8–9 bettersociety betterenvironment How we support How we reduce our communities and our environmental develop our people impact Strategic framework on pages 12–13 Contents Strategic Report bettersociety Governance Report 1 Highlights 24 – Workplace 46 Board of Directors 2 At a glance 26 – Communities 50 Executive Committee 4 Chairman’s Statement 26 – Products 52 Chairman’s Statement on 7 Reasons why RB delivers betterenvironment Corporate Governance 8 Chief Executive’s Review 27 – Greenhouse gas emissions 54 Corporate Governance Statement 10 Our unique culture 28 – Water 60 Nomination Committee Report 12 Strategic framework 28 – Waste 61 Audit Committee Report 14 Our market and resources 29 – Sourcing 66 Directors’ Remuneration Report betterfinancials 30 Our operating model 68 Our remuneration at a glance 16 – Our strategy to deliver 32 Our operating model in action 70 Annual Report on Remuneration 17 – Organisation 34 Creating stakeholder value 79 Directors’ Remuneration Policy 19 – Powermarkets 36 Financial Review 85 Report of the Directors 20 – Powerbrands 40 Strategic Risks 88 Directors’ Statement of Responsibilities 22 – Virtuous earnings model Financial Statements 89 Financial Statements Any information contained in the 2015 Annual Report and Financial Statements on the price at which shares or other securities in Reckitt Benckiser Group plc have been bought or sold in the past, or on the yield on such shares or other securities, should not be relied upon as a guide to future performance.
    [Show full text]
  • List of Active Bayer Companies with at Least a Share of 50% Last Update: 17.8.2020 Country Company
    List of active Bayer companies with at least a share of 50% last update: 17.8.2020 Country Company Algeria Bayer Algerie S.P.A. Argentina Bayer S.A. Argentina Biagro S.A. Argentina Monsanto Argentina SRL Australia Bayer Australia Limited Australia Bayer CropScience Holdings Pty Ltd Australia Bayer CropScience Pty Limited Australia Cotton Growers Services Pty. Limited Australia Imaxeon Pty. Ltd. Australia Monsanto Australia Pty Ltd Bangladesh Bayer CropScience Ltd. Belgium Bayer Agriculture BVBA Belgium Bayer CropScience NV Belgium Bayer NV Bermuda MonSure Limited Bolivia Bayer Boliviana Ltda Bolivia Monsanto Bolivia S.A. Bosnia & Herzeg. Bayer d.o.o. Sarajevo Brazil Alkagro do Brasil Ltda Brazil Bayer S.A. Brazil D&PL Brasil Ltda Brazil Monsanto do Brasil Ltda. Brazil Rede Agro Fidelidade e Intermediacao S.A. Brazil Schering do Brasil Química e Farmacêutica Ltda. Brazil Stoneville Brasil Ltda. Bulgaria Bayer Bulgaria EOOD Burkina Faso Monsanto Burkina Faso SARL Chile Bayer Finance & Portfolio Management S.A. Chile Bayer Finance Ltda. Chile Bayer S.A. Chile Monsanto Chile, S.A. Costa Rica Bayer Business Services Costa Rica, SRL Costa Rica Bayer Medical S.R.L. Costa Rica Bayer S.A. Curacao Pianosa B.V. Germany Adverio Pharma GmbH - 1 - List of active Bayer companies with at least a share of 50% last update: 17.8.2020 Country Company Germany AgrEvo Verwaltungsgesellschaft mbH Germany Alcafleu Management GmbH & Co. KG Germany BGI Deutschland GmbH Germany Bayer 04 Immobilien GmbH Germany Bayer 04 Leverkusen Fußball GmbH Germany Bayer 04 Leverkusen
    [Show full text]
  • Local Businesses – Large and Small
    Local Businesses – Large and Small The details of the local businesses documented below have been researched by the Local History Group. Thomas Glover & Son Thomas Glover & Son, elastic web and fabric manufacturers appeared in the Post Office Directory for Nottinghamshire in 1855. The company is recorded as having several addresses in Nottingham, however it had disappeared from the directory by 1900, returning in 1925 described as a surgical hosier in Chesterfield Street, Carlton. The firm remained at that address until the 1970s. The company’s buildings were on both sides of Chesterfield Street but are now demolished, new houses being built on the side. Turney Brothers In 1861 two brothers, Edward and John Turney built a tannery and began to make leather on a site next to the River Trent and the adjacent canal in Nottingham, known as Sneinton Island. The first buildings took up only a fraction of the space that by the 1920s had developed into a large site with labour-saving machinery imported from many countries. They traded under the name of Turney Brothers and had offices in London, Leicester and Manchester. Edward left some years after the commencement of the company and the driving force was John Turney who was in sole charge for over a quarter of a century. In 1888 the company re-organised into a Limited Company, John being chairman. John led an exceptionally distinguished social, political and commercial life. He was a member of Nottingham Corporation for 46 years, and became Sheriff and then Alderman in 1879 and Mayor for two years 1886 – 1888.
    [Show full text]
  • Steven Sanders, Et Al. V. Bayer (AG) Aktiengesellschaft, Et Al. 03-CV-1546-Second Consolidated Amended Complaint
    Q,^.IGiNAL &&,iN 2i 4- L UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK -_DOF x Consolidated Civil Action IN RE BAYER AG SECURITIES No. 03 CV 1546 (WHP) LITIGATION Class Action x 71 :n = SECOND CONSOLIDATED AMENDED COMPLAINT Jury Trial Demand MILBERG WEISS BERSHAD & SCHULMAN LLP Melvyn I. Weiss (MW-1392) Michael C . Spencer (MS-8874) Lee A. Weiss (LW-1130) Jennifer Sclar (JS-7313) One Pennsylvania Plaza New York, NY 10119 (212) 594-5300 Attorneys for Lead Plaintiff January 14, 2005 i • ' Table of Contents Page SUMMARY OF CLAIMS ...............................................................................................................2 JURISDICTION AND VENUE ...................................................................................................... 8 A. General Jurisdiction and Venue ............................................................................... 8 B. Subject Matter Jurisdiction Over Claims of Foreign Purchasers on Foreign Exchanges ................................................................................................................ 8 PARTIES .......................................................................................................................................12 RELEVANT EVENTS ..................................................................................................................14 A. Background of the Statin Market ...........................................................................14 B. FDA Approval and Introduction of Baycol; Early Safety Warnings
    [Show full text]
  • Securities and Exchange Commission on February 20, 2018
    As filed with the Securities and Exchange Commission on February 20, 2018. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Or ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 Or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Or SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report ____________ For the transition period from N/A to N/A Commission file number: 001-14930 HSBC Holdings plc (Exact name of Registrant as specified in its charter) N/A United Kingdom (Translation of Registrant’s name into English) (Jurisdiction of incorporation or organisation) 8 Canada Square London E14 5HQ United Kingdom (Address of principal executive offices) Gavin A Francis 8 Canada Square London E14 5HQ United Kingdom Tel +44 (0) 20 7991 8888 Fax +44 (0) 20 7992 4880 (Name, Telephone, Email and/or Facsimile number and Address of Company Contact Person) Securities registered or to be registered pursuant to Section 12(b) of the Securities Exchange Act of 1934: Title of each class Name of each exchange on which registered Ordinary Shares, nominal value US$0.50 each. London Stock Exchange Hong Kong Stock Exchange Euronext Paris Bermuda Stock Exchange New York Stock Exchange* American Depository Shares, each representing 5 New York Stock Exchange Ordinary Shares of nominal value US$0.50 each.
    [Show full text]
  • Fund Holdings
    Wilmington International Fund as of 7/31/2021 (Portfolio composition is subject to change) ISSUER NAME % OF ASSETS ISHARES MSCI CANADA ETF 3.48% TAIWAN SEMICONDUCTOR MANUFACTURING CO LTD 2.61% DREYFUS GOVT CASH MGMT-I 1.83% SAMSUNG ELECTRONICS CO LTD 1.79% SPDR S&P GLOBAL NATURAL RESOURCES ETF 1.67% MSCI INDIA FUTURE SEP21 1.58% TENCENT HOLDINGS LTD 1.39% ASML HOLDING NV 1.29% DSV PANALPINA A/S 0.99% HDFC BANK LTD 0.86% AIA GROUP LTD 0.86% ALIBABA GROUP HOLDING LTD 0.82% TECHTRONIC INDUSTRIES CO LTD 0.79% JAMES HARDIE INDUSTRIES PLC 0.78% DREYFUS GOVT CASH MGMT-I 0.75% INFINEON TECHNOLOGIES AG 0.74% SIKA AG 0.72% NOVO NORDISK A/S 0.71% BHP GROUP LTD 0.69% PARTNERS GROUP HOLDING AG 0.65% NAVER CORP 0.61% HUTCHMED CHINA LTD 0.59% LVMH MOET HENNESSY LOUIS VUITTON SE 0.59% TOYOTA MOTOR CORP 0.59% HEXAGON AB 0.57% SAP SE 0.57% SK MATERIALS CO LTD 0.55% MEDIATEK INC 0.55% ADIDAS AG 0.54% ZALANDO SE 0.54% RIO TINTO LTD 0.52% MERIDA INDUSTRY CO LTD 0.52% HITACHI LTD 0.51% CSL LTD 0.51% SONY GROUP CORP 0.50% ATLAS COPCO AB 0.49% DASSAULT SYSTEMES SE 0.49% OVERSEA-CHINESE BANKING CORP LTD 0.49% KINGSPAN GROUP PLC 0.48% L'OREAL SA 0.48% ASSA ABLOY AB 0.46% JD.COM INC 0.46% RESMED INC 0.44% COLOPLAST A/S 0.44% CRODA INTERNATIONAL PLC 0.41% AUSTRALIA & NEW ZEALAND BANKING GROUP LTD 0.41% STRAUMANN HOLDING AG 0.41% AMBU A/S 0.40% LG CHEM LTD 0.40% LVMH MOET HENNESSY LOUIS VUITTON SE 0.39% SOFTBANK GROUP CORP 0.39% NOVARTIS AG 0.38% HONDA MOTOR CO LTD 0.37% TOMRA SYSTEMS ASA 0.37% IMCD NV 0.37% HONG KONG EXCHANGES & CLEARING LTD 0.36% AGC INC 0.36% ADYEN
    [Show full text]
  • Corporate Finance Guide 2021 CORPORATE FINANCE GUIDE SPECIAL | CORPORATE
    01/06/2021 15:30 15:30 01/06/2021 01/06/2021 1 1 cover.indd cover.indd Guide Guide Finance Finance Corporate Corporate MIDLANDS BUSINESS INSIDER www.midlandsbusinessinsider.com JULY 2021 JULY midlands businessinsider WEST ™ MIDLANDS insiderEDITION VOL.29 NO.7 £10 JULY 2021 West Midlands Mayor What does business want from Andy Street’s second term? CITY OF CULTURE CITY OFCULTURE Wolverhampton The new home of green construction | SMEGUIDE Mental health | MENTAL HEALTH HEALTH MENTAL Helping a colleague on the edge | RESIDENTIAL AWARDS RESIDENTIALAWARDS | CORPORATE FINANCEGUIDESPECIAL CORPORATE Guide Guide 2021 Corporate Finance Corporate MIDLANDS | CIRCULARECONOMY FIREDHOW A YEAR AS CITY OF CULTURE UP! IS VOL.29 N VOL.29 SPARKING GROWTH IN COVENTRY O 7 MBI July 2021 cover MASTER.indd 1 02/06/2021 15:00 Optimising outcomes for our clients no matter what their destination DLA Piper has been the No 1 M&A law firm, both in the UK and globally, for each of the past 11 years. Trusted adviser to: Put simply, we do things that other law firms cannot. Times 2 SISTERS FOOD GROUP may change, but our qualities do not. Our clients trust us with Advised on the GBP246m sale of part of Fox’s Biscuits to their most important, strategic and transformational M&A and Ferrero Group. ECM transactions. We use our market and sector intelligence and unrivalled deal execution experience to drive and obtain NOBLE GROUP optimal outcomes for our clients, no matter what the deal type, Advised on the sale of chilled dessert brand Gü to Exponent the transaction process, the geography or the counter-party.
    [Show full text]
  • Rb-Annual-Report-2017.Pdf
    Reckitt Benckiser Group plc(RB) Healthier Annual Report and Financial Statements 2017 Statements Financial and Report Annual Lives, Happier Homes Bringing Our Purpose to Life Reckitt Benckiser Group plc (RB) Annual Report and Financial Statements 2017 RB is inspired by a vision of a world where people are healthier and live better. We continually invest and innovate to find new ways for people to look after themselves, their families and their homes. We believe passionately in doing things the right way and have a culture that pushes us to outperform, every day. Contents Strategic Report Transformation of RB page 01 Highlights 02 Our business model 04 Chairman’s Statement 6 06 Chief Executive’s Statement 10 Strategic objectives, targets and key performance indicators 14 betterbusiness in action 20 bettersociety in action 22 betterenvironment in action 24 Operating review 30 Megatrends 32 Health 34 Hygiene Home Strategy page 36 Financial review 42 Our framework for risk management betterbusiness 10 Governance 52 Board of Directors 56 Executive Committee bettersociety 58 Corporate Governance– Chairman’s Statement 61 Corporate Governance Statement betterenvironment 69 Nomination Committee Report 71 Audit Committee Report 76 Corporate Responsibility, Sustainability, Ethics and Compliance Committee Report Mead Johnson Nutrition Sale of 78 Directors’ Remuneration Report integration RB Food 82 Remuneration Policy at a glance 83 Implementation of specific commitments made to page Shareholders for 2017 84 Annual Report on Remuneration 95 Report
    [Show full text]